The 2015 ASCO Annual Meeting took place May 29 through June 2 in Chicago, Illinois.

Panobinostat combos can treat rel/ref MM



ASCO2015_RodneyWhite_230.jpg
Crowd at ASCO 2015
©ASCO/Rodney White

Combination regimens including the histone deacetylase inhibitor panobinostat can produce durable responses and prolong progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (MM), according to research presented at the 2015 ASCO Annual Meeting. In a phase 2 trial, panobinostat plus lenalidomide and dexamethasone produced durable responses, even... [Read Article]

CAR T-cell therapy seems feasible for NHL, MM



ASCO2015_crowd_Rodney_White_230.jpg
Attendees at ASCO 2015
©ASCO/Rodney White

The CD19-directed chimeric antigen receptor (CAR) T-cell therapy CTL019 has shown promise for treating non-Hodgkin lymphoma (NHL) and may be a feasible treatment option for multiple myeloma (MM) as well, according to researchers. In an ongoing phase 2 trial, CTL019 has produced durable responses in patients with relapsed... [Read Article]

A better FLT3 inhibitor for AML?



ASCO215_attendees_talk_Scott_Morgan_230.jpg
Attendees at ASCO 2015
© ASCO/Scott Morgan

A dual inhibitor of FLT3 and Axl may produce more durable responses than other FLT3 inhibitors and improve survival in patients with FLT3-positive, relapsed or refractory acute myeloid leukemia (AML), according to a speaker at the 2015 ASCO Annual Meeting. The FLT3/Axl inhibitor, ASP2215, has not been... [Read Article]

BCL-2 inhibitor shows potential for treating MM



ASCO2015_directions_Zach_Boyden-Holmes_220.jpg
Staff member giving directions
to an attendee at ASCO 2015
© ASCO/Zach Boyden-Holmes

A BCL-2 inhibitor that has shown activity in patients with chronic and acute leukemias could be a feasible treatment option for multiple myeloma (MM) too, according to research presented at the 2015 ASCO Annual Meeting. In a pair of phase... [Read Article]

CAR produces high CR rate in adults with rel/ref ALL



ASCO2015_session_ipad_Max_Gersh_220.jpg
Audience during a session at 
the 2015 ASCO Annual Meeting
© ASCO/Max Gersh

A CD19-targeted chimeric antigen receptor (CAR) T-cell therapy can provide durable complete responses (CRs) or a bridge to allogeneic transplant in adults with relapsed or refractory acute lymphoblastic leukemia (ALL), updated results of a phase 1 study suggest. The therapy,... [Read Article]

No survival difference with allo- or auto-SCT in PTCL



ASCO2015_stairs_Max_Gersh_230.jpg
Attendees at ASCO 2015
© ASCO/Max Gersh

Allogeneic and autologous transplants produce similar survival rates when used as first-line therapy in younger patients with peripheral T-cell lymphoma (PTCL), according to interim results of the AATT trial. The study also showed that deaths among patients who received autologous stem cell transplants (auto-SCTs) were a result... [Read Article]

Triplet shows early promise for relapsed CLL, NHL



ASCO2015_RodneyWhite_230.jpg
Crowd at ASCO 2015
©ASCO/Rodney White

A 3-drug combination is safe and highly active in certain patients with relapsed B-cell malignancies, according to a speaker at the 2015 ASCO Annual Meeting. The combination consists of the anti-CD20 monoclonal antibody ublituximab, the PI3Kδ inhibitor TGR-1202, and the BTK inhibitor ibrutinib. In a small, phase 1... [Read Article]

LSC phenotypes correlate with prognosis in AML



ASCO2015_crowd_Rodney_White_230.jpg
Crowd at ASCO 2015
© ASCO/Rodney White

Researchers say they have identified 3 leukemia stem cell (LSC) phenotypes that are correlated with cytogenetic/molecular abnormalities and prognosis in acute myeloid leukemia (AML). The investigators believe this knowledge could aid risk stratification of AML patients, particularly those without identifiable risk factors. The findings may also pave... [Read Article]

Single agent can treat resistant MM



lonial-sagar_ASCO15_Todd_Buchanan_230.jpg
Sagar Lonial, MD
© ASCO/Todd Buchanan

The anti-CD38 monoclonal antibody daratumumab can be effective as a stand-alone therapy for some heavily pretreated patients with multiple myeloma (MM), results of an ongoing phase 2 trial suggest. The study, known as SIRIUS or MMY2002, included more than 100 patients who had received 3 or more prior... [Read Article]

Drug prolongs PFS in indolent, refractory NHL



ASCO2015_info_strt_230.jpg
Inside McCormick Place, site of
the 2015 ASCO Annual Meeting

Adding obinutuzumab to treatment with bendamustine improves progression-free survival (PFS) in patients with rituximab-refractory, indolent non-Hodgkin lymphoma (NHL), interim results of the phase 3 GADOLIN trial suggest. Study investigators said patients who received obinutuzumab and bendamustine followed by obinutuzumab maintenance had roughly double the... [Read Article]